Paper · 42979040

Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance.

Zhou Y. Front Immunol, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance. Papers, record 42979040. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42979040

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance.
Journal: Front Immunol
Year: 2026
Publication types: Journal Article, Review
PubMed: https://pubmed.ncbi.nlm.nih.gov/42979040/
DOI: https://doi.org/10.3389/fimmu.2026.1955015
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13729121/
The journal: https://conductscience.org/library/journal-index/101560960
Revised in PubMed: 2026-11-05

Source PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	Kind	ORCID iD
1	Zhou Y	Yuqi

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Flavanones	Major topic
Pancreatic Neoplasms	Major topic
Tumor Microenvironment	Major topic
Drug Resistance, Neoplasm	Major topic
Gastrointestinal Microbiome	Major topic
Humans
Metabolic Reprogramming
Animals
Signal Transduction

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References90

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	36,010,993	The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC.	Cancers (Basel)	2022	https://conductscience.org/library/papers/36010993	PubMed
2	37,375,237	Intracellular Redox Behavior of Quercetin and Resveratrol Singly and in Mixtures.	Molecules	2023	https://conductscience.org/library/papers/37375237	PubMed
3	32,398,706	The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.	Nat Rev Clin Oncol	2020	https://conductscience.org/library/papers/32398706	PubMed
4	22,888,839	Flavonoids and cancer prevention: a review of the evidence.	J Nutr Gerontol Geriatr	2012	https://conductscience.org/library/papers/22888839	PubMed
5	35,022,204	Hallmarks of Cancer: New Dimensions.	Cancer Discov	2022	https://conductscience.org/library/papers/35022204	PubMed
6	28,050,011	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.	Nat Rev Cancer	2017	https://conductscience.org/library/papers/28050011	PubMed
7	30,634,637	The Therapeutic Potential of Naringenin: A Review of Clinical Trials.	Pharmaceuticals (Basel)	2019	https://conductscience.org/library/papers/30634637	PubMed
8	28,476,144	Multi-omics approaches to disease.	Genome Biol	2017	https://conductscience.org/library/papers/28476144	PubMed
9	31,578,522	The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL.	Nature	2019	https://conductscience.org/library/papers/31578522	PubMed
10	29,567,829	The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression.	Cancer Discov	2018	https://conductscience.org/library/papers/29567829	PubMed

1 to 10 of 90

See all 90 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42979040

GET https://conductscience.org/api/papers/v1/42979040/references?page=2

API reference For AI assistants